A Case Study of Clinical Response to Rucaparib in a Patient with Metastatic Castration-Resistant Prostate Cancer and a RAD51B Alteration

PARP inhibitors, such as rucaparib, have been well characterized in metastatic castration-resistant prostate cancer (mCRPC) associated with BRCA alterations, and the clinical activity of these agents has also been evaluated in patients with mCRPC associated with alterations in other non-BRCA DNA dam...

Descripción completa

Detalles Bibliográficos
Autores principales: Sautois, Brieuc, Loehr, Andrea, Watkins, Simon P., Schroeder, Hélène, Abida, Wassim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221801/
https://www.ncbi.nlm.nih.gov/pubmed/35735442
http://dx.doi.org/10.3390/curroncol29060333

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221801/
https://www.ncbi.nlm.nih.gov/pubmed/35735442
http://dx.doi.org/10.3390/curroncol29060333

Ejemplares similares